Zhang Peng, Yang Jing, Liu Yongyong, Zhou Qing, Xue Caiqiang, Zhang Bin, Li Yumin
Department of Pathology, Lanzhou University Second Hospital, Lanzhou, Gansu, China.
Department of Pathology, Chengdu Integrated Traditional Chinese Medicine (TCM) and Western Medicine Hospital, Chengdu, Sichuan, China.
Front Oncol. 2025 Apr 11;15:1516966. doi: 10.3389/fonc.2025.1516966. eCollection 2025.
Gastric adenosquamous carcinoma (ASC) is an exceedingly rare neoplasm. Its infrequent occurrence has resulted in sparse literature on its diagnosis and management, presenting considerable challenges for clinical practice.
A 70-year-old male presented with epigastric pain and, upon gastroscopy and CT imaging, was found to have a mass in the gastric antrum. Histopathological analysis confirmed the diagnosis of adenosquamous carcinoma. Immunohistochemical staining revealed a loss of PMS2 and MLH-1 expression, while molecular analysis confirmed MLH-1 methylation, suggesting a microsatellite instability-high (MSI-H) phenotype. The PD-L1 combined positive score (CPS) was remarkably elevated at 80. Postoperatively, the patient received six cycles of oxaliplatin in conjunction with PD-1 inhibitor therapy. At the one-year follow-up, the patient remained in long-term remission, with no evidence of recurrence.
This case underscores the potential efficacy of integrating surgery, chemotherapy, and immunotherapy in managing gastric ASC, particularly in the context of MSI-H and elevated PD-L1 expression. It further emphasizes the critical role of comprehensive molecular profiling in guiding personalized therapeutic strategies for such rare malignancies. Further research and additional case reports are imperative to establish optimal management protocols for gastric ASC and to enhance long-term outcomes.
胃腺鳞癌(ASC)是一种极其罕见的肿瘤。其罕见性导致关于其诊断和治疗的文献稀少,给临床实践带来了相当大的挑战。
一名70岁男性因上腹部疼痛就诊,经胃镜检查和CT成像发现胃窦部有一个肿块。组织病理学分析确诊为腺鳞癌。免疫组织化学染色显示PMS2和MLH-1表达缺失,而分子分析证实MLH-1甲基化,提示微卫星高度不稳定(MSI-H)表型。PD-L1联合阳性评分(CPS)显著升高至80。术后,患者接受了六个周期的奥沙利铂联合PD-1抑制剂治疗。在一年的随访中,患者保持长期缓解,无复发迹象。
本病例强调了手术、化疗和免疫治疗相结合在治疗胃ASC中的潜在疗效,特别是在MSI-H和PD-L1表达升高的情况下。它进一步强调了全面分子谱分析在指导此类罕见恶性肿瘤的个性化治疗策略中的关键作用。进一步的研究和更多的病例报告对于建立胃ASC的最佳管理方案和改善长期预后至关重要。